The Effectiveness of Adding Braun Anastomosis to Standard Child Reconstruction After Pancreatoduodenectomy
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Jan 24, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called REMBRANDT, is looking at whether adding an extra connection, known as a 'Braun anastomosis,' to the standard surgery for pancreatic cancer can help patients avoid a common issue called delayed gastric emptying. Delayed gastric emptying means that the stomach takes longer than usual to empty its contents, which can be uncomfortable and affect recovery. The trial is actively recruiting participants who are over 18 years old and will be undergoing open pancreatoduodenectomy, a surgery that removes part of the pancreas and is often necessary for pancreatic disease.
To participate, individuals need to be able to read and understand Dutch, as the study materials will be in that language. Some people may not be eligible if they have had certain previous surgeries, are pregnant, or have specific health conditions that might affect their digestive system. Participants in this trial can expect to receive standard care along with the additional surgical connection, and their progress will be monitored to see if this approach helps improve their recovery after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Undergoing open pancreatoduodenectomy
- • Provided informed consent
- • Age over 18 years
- Exclusion Criteria:
- • Insufficient control of the Dutch language to read the patient information and to fill out the questionnaires in Dutch hospitals
- • Previous bariatric surgery (such as Roux-en-Y gastric bypass, gastric sleeve)
- • Pregnancy
- • Bowel motility disorders
- • Minimally invasive pancreatoduodenectomy
- • Gastric outlet syndrome
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, , Netherlands
Leiden, , Netherlands
Rotterdam, , Netherlands
Eindhoven, , Netherlands
Nieuwegein, , Netherlands
Enschede, , Netherlands
Nijmegen, , Netherlands
Leeuwarden, , Netherlands
Maastricht, , Netherlands
Amsterdam, , Netherlands
Zwolle, , Netherlands
Groningen, , Netherlands
Patients applied
Trial Officials
Martijn WJ Stommel, MD, PhD
Principal Investigator
Radboud University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials